BioNxt Solutions
BioNxt Solutions is a Vancouver-based, publicly traded clinical-stage biopharmaceutical company developing a proprietary sublingual oral dissolvable film drug delivery platform, with a lead cladribine ODF asset for multiple sclerosis and an early-stage semaglutide ODF program targeting the GLP-1 obesity market.
- Company typePublic
- Founded2018
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioNxt Solutions does
BioNxt Solutions Inc. is a Vancouver, Canada-based, publicly traded (TSE:BNXT) clinical-stage biopharmaceutical company developing a proprietary sublingual oral dissolvable film (ODF) drug delivery platform for reformulating established therapeutics into swallow-free, needle-free dosage forms. The lead asset, BNT23001, is a patented sublingual cladribine ODF targeting multiple sclerosis and myasthenia gravis, with preclinical data showing approximately 40% higher blood exposure than conventional oral cladribine tablets. A second program applies the same platform to GLP-1 receptor agonists, starting with semaglutide for obesity, metabolic disorders, and type 2 diabetes, with plans to extend to tirzepatide and liraglutide.
The technology stack combines formulation know-how for ODF manufacture with a pending drug chaperone technology (under non-binding LOI) intended to enhance drug stability, absorption, and delivery consistency. Clinical-grade GMP production of the Cladribine ODF was completed in April 2026 at a Munich contract manufacturing partner to supply the planned first-in-human bioavailability study CBN26001. Semaglutide ODF development is conducted with German partner Gen-Plus GmbH. The intellectual property portfolio comprises granted European Patent No. 4539857 (effective March 11, 2026, valid through at least June 14, 2043 across up to 39 EPC states), an Eurasian patent across 8 member states, and a Track One priority filing at the USPTO.
BioNxt operates without commercialized products or product revenue. Its stated business model is partnership-driven: exclusive licensing agreements with pharmaceutical counterparties, co-development collaborations, and royalty-based supply arrangements, with a Business Development & Licensing specialist advisor engaged in June 2026 to commercialize BNT23001. The company is funded primarily through repeated non-brokered private placements, supplemented by a convertible debenture tranche in July 2025, with proceeds directed to European R&D, IP, and working capital. Headcount sits at 11–50 employees and the company is led by co-founder and CEO Hugh Rogers, co-founder and CFO Wolfgang Probst, and co-founder and director Raimar Löbenberg.
BioNxt Solutions firmographics
Firmographics- Name
- BioNxt Solutions
- Legal name
- BioNxt Solutions Inc.
- Website
- https://bionxt.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioNxt Solutions is a Vancouver-based, publicly traded clinical-stage biopharmaceutical company developing a proprietary sublingual oral dissolvable film drug delivery platform, with a lead cladribine ODF asset for multiple sclerosis and an early-stage semaglutide ODF program targeting the GLP-1 obesity market.
- Ownership category
- akta.pro rank
BioNxt Solutions industry classification
Industry- Product category
- Pharmaceutical Drug Delivery
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
Keywords
Where BioNxt Solutions is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
BioNxt Solutions business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing Agreements: The company plans to generate revenue through licensing its drug delivery technology and patented formulations to pharmaceutical partners, including upfront payments, milestone payments, and ongoing royalties.
- Co-development Collaborations: Revenue from joint development partnerships with pharmaceutical companies where BioNxt contributes its ODF platform technology in exchange for development funding and commercialization rights.
- Royalty-based Supply Arrangements: Potential royalty-based supply arrangements with pharmaceutical partners for commercialized products using the sublingual drug delivery platform.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
BioNxt Solutions product offering
Product offeringCore offering
BioNxt Solutions develops and commercializes proprietary sublingual oral dissolvable film (ODF) drug delivery formulations for peptide and small molecule therapeutics. Its lead product candidate BNT23001 is a swallow-free, needle-free sublingual cladribine ODF for multiple sclerosis, demonstrated to provide approximately 40% higher blood exposure than conventional oral tablets in preclinical studies. The company also advances a Semaglutide ODF program as the lead application of a broader GLP-1 ODF platform.
Product overview
BioNxt Solutions is a bioscience company developing a proprietary sublingual oral dissolvable film (ODF) drug delivery platform. The company's core product is BNT23001, a patented sublingual Cladribine ODF for multiple sclerosis treatment. BioNxt is advancing a Semaglutide ODF program as the first application of its broader GLP-1 ODF Platform strategy, targeting obesity, metabolic disorders, and type 2 diabetes. The platform technology is being expanded to include tirzepatide and liraglutide formulations. The company has also secured drug chaperone technology to enhance its ODF platform and acquired rights to a sublingual formulation for oncology treatments. Development is conducted in Germany through partner Gen-Plus GmbH, with operations in North America and Europe.
Differentiator
Problem solved
Functional benefit
Products and services
- BNT23001 (Sublingual Cladribine Oral Dissolvable Film) Patented sublingual cladribine orally dissolvable film formulation intended as a swallow-free, needle-free alternative to conventional Mavenclad tablets for multiple sclerosis and myasthenia gravis treatment. Licensed to pharmaceutical partners for commercialization.
- Semaglutide Oral Dissolvable Film Program Oral thin-film formulation of semaglutide being developed for sublingual delivery of GLP-1 receptor agonist therapy, intended for pharmaceutical partners commercializing obesity and metabolic disorder treatments.
- Sublingual Oncology Formulation Novel sublingual drug formulation for oncology and immunosuppressant treatments being co-developed with a European-based chemotherapy company, expanding BioNxt's intellectual property portfolio and product pipeline.
Quantifiable outcome
- Approximately 40% higher blood exposure compared to conventional oral tablets in preclinical studies
- +2 more outcomes
Companies that use BioNxt Solutions
Customer profileSegments3 records
Ideal customer profiles3 records
BioNxt Solutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BioNxt Solutions partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- Business Development & Licensing Specialist AdvisorcoreEngaged advisor to support commercialization and partnering strategy for BNT23001, the patented sublingual Cladribine orally dissolvable film formulation for multiple sclerosis treatment.
- Gen-Plus GmbHcoreGerman pharmaceutical development partner collaborating with BioNxt on the Semaglutide oral dissolvable film program. Gen-Plus provides active pharmaceutical development services for the GLP-1 ODF program targeting obesity, metabolic disorders, and type 2 diabetes.
- Contract Manufacturing Partner (Munich, Germany)coreContract manufacturing partner in Munich, Germany responsible for GMP production of clinical-grade sublingual Cladribine oral thin film for human bioavailability studies.
- Eurasian Patent Organization LicenseemajorNon-binding letter of intent establishing exclusive negotiation framework toward potential regional licensing agreement for sublingual cladribine oral thin film within Eurasian Patent Organization member states, with 60-day exclusivity period.
- Third-party Biotechnology DevelopercoreNon-binding letter of intent to secure exclusive rights to advanced drug chaperone technology for oral dissolvable thin-film applications to enhance drug stability, absorption efficiency, and delivery consistency.
- European-based Chemotherapy CompanycoreLetter agreement signed to acquire 100% interest in IP and co-develop a sublingual drug formulation for oncology and immunosuppressant treatments.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
BioNxt Solutions competitors and assessment
Company assessmentDirect peers
- ARx LLC: Oral thin film drug delivery company developing sublingual and buccal films for multiple therapeutic areas. Closely comparable as a smaller ODF-focused drug delivery specialist with a partnership-driven commercialization model.
- Aquestive Therapeutics: Specialty pharma company commercializing sublingual and oral soluble film drug delivery products including Sympazan and Libervant. Directly comparable as a sublingual ODF platform company focused on reformulating approved molecules with proprietary thin-film technology.
- IntelGenx Technologies: Developer of oral thin-film and VersaFilm drug delivery platforms for pharmaceutical partners, with a comparable focus on reformulating small molecules via oral dissolvable/sublingual formats. Mirrors BioNxt's licensing-driven, small-cap specialty pharma model.
- ZIM Laboratories: Specialty pharma and CDMO focused on oral thin film (Oralthin), orally disintegrating tablets, and taste-masked formulations. Operates as both an ODF technology licensor and contract manufacturer, comparable to BioNxt's sublingual ODF offering.
- LTS Lohmann Therapie-Systeme: Established German developer and manufacturer of oral thin-film and transdermal drug delivery systems serving global pharma partners. Directly comparable as a European-based ODF platform licensor with GMP manufacturing capabilities similar to BioNxt's Munich partner arrangement.
- Cure Pharmaceutical (The CURE Group): Developer of oral thin-film dosage forms for pharmaceutical compounds including cannabinoids and therapeutics. Comparable as an ODF drug delivery platform company pursuing licensing and partnership revenues.
- Emisphere Technologies (Eligen technology): Develops the Eligen carrier-based oral delivery technology for small molecules and peptides, focused on enabling oral administration of peptides and other poorly absorbed drugs. Comparable to BioNxt's GLP-1 ODF ambition of delivering injectable peptide therapeutics orally.
Regional players
- Adhex Pharma: European-based developer and manufacturer of transdermal and oral thin film drug delivery systems. Comparable as a European ODF specialist, though primarily serving EU regional customers rather than competing directly in BioNxt's core indications.
Broad incumbents
- Merck KGaA (Mavenclad franchise): Global pharmaceutical company marketing Mavenclad (oral cladribine) for multiple sclerosis, generating approximately €1.2 billion in 2025 revenues. Relevant incumbent for BNT23001's competitive context in MS, though broader portfolio spans many therapy areas.
Emerging players
- Tapemark: Contract developer of oral dissolvable films and transdermal patches for pharmaceutical partners. Comparable as a smaller ODF/CDMO service provider in BioNxt's broader drug delivery ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
BioNxt Solutions social profiles
Digital presenceBioNxt Solutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioNxt Solutions leadership team
Management profileNumber of profiles
Profiles3 records
BioNxt Solutions subsidiaries and ownership
Company hierarchySubsidiaries1 record
BioNxt Solutions funding detail
Funding detailFunding overview
Funding rounds7 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioNxt Solutions M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioNxt Solutions
What does BioNxt Solutions do?
BioNxt Solutions develops and commercializes proprietary sublingual oral dissolvable film (ODF) drug delivery formulations for peptide and small molecule therapeutics. Its lead product candidate BNT23001 is a swallow-free, needle-free sublingual cladribine ODF for multiple sclerosis, demonstrated to provide approximately 40% higher blood exposure than conventional oral tablets in preclinical studies. The company also advances a Semaglutide ODF program as the lead application of a broader GLP-1 ODF platform.
Is BioNxt Solutions a public or private company?
BioNxt Solutions is a public company. It is classified as public and is currently operating.
When was BioNxt Solutions founded?
BioNxt Solutions was founded in 2018. It employs 11 to 50 people.
Where is BioNxt Solutions based?
BioNxt Solutions is headquartered in Vancouver, Canada, in the North America region.
How does BioNxt Solutions make money?
Three revenue lines are on record. Licensing Agreements are the primary driver. The others are co-development Collaborations and royalty-based Supply Arrangements.
Who are BioNxt Solutions's main competitors?
Direct peers on record are ARx LLC, Aquestive Therapeutics, IntelGenx Technologies, ZIM Laboratories, LTS Lohmann Therapie-Systeme, Cure Pharmaceutical (The CURE Group) and Emisphere Technologies (Eligen technology). Adhex Pharma is listed as a regional player. Merck KGaA (Mavenclad franchise) is listed as a broad incumbent. Tapemark is listed as an emerging player.
Does BioNxt Solutions have an API?
No public API is recorded for BioNxt Solutions.
What industry is BioNxt Solutions in?
BioNxt Solutions's product category is Pharmaceutical Drug Delivery. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.